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The aim: To evaluate anticancer activity of vaccination with chicken embryo proteins (CEP) applied in different schedules. Materials 
and Methods: C57Bl mice were vaccinated with CEP before (prophylactic schedule) or after (different therapeutic schedules with 
or without preliminary tumor removal) the Lewis lung carcinoma cells transplantation. The latent period of tumor development, tumor 
volume and metastasis rate were evaluated. Results: Potent antimetastatic effect of CEP-based vaccination was seen in case of thera-
peutic regimen after primary tumor removal. The metastasis inhibition index (MII) reached 96.9 and 97.8% on 18th and 34th day after 
tumor removal, respectively. When CEP vaccination was performed in the settings of therapeutic regimen without primary tumor 
removal the anticancer effect was evident only if vaccinations started as early as 24 h after the cancer cells injections. The highest MII 
achieved in such condition was 77.6%, tumor volume in the group of vaccinated animals was by 53.1–42.1% lower than in the control 
tumor-bearing mice. CEP vaccination before tumor challenge (prophylactic immunization) led to a statistically significant prolonga-
tion of the latent period of tumor development, a reduction of tumor volume (35.8–48.8% compared to control unvaccinated mice) 
and a marked inhibition of metastasis (MII was 71.1%). Conclusion: Vaccination based on CEP exhibited both prophylactic and 
therapeutic anticancer effects. The last one is more pronounced when the vaccination starts shortly after the primary tumor resection.
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The development of xenogeneic anticancer vac-
cines (XAV) started at the end of the 1990s, when 
it was shown that the use of xenogeneic analogues 
of tumor associated antigens enables the body 
to overcome immunological toleration for its own 
proteins [1]. Now, it is proven that a number of tumor 
associated antigens and protein have their counter-
parts of animal or avian origin which can serve as an-
tigens in XAV. These proteins or genes are exploited 
in the construction of XAVs, some of which have been 
shown to have anticancer effect [2, 3]. Some XAV 
successfully passed I–II phases of clinical trials. Their 
safety and ability to induce immune response without 
autoimmune complications have been proven [4–8]. 
Among others, genes and proteins of chicken origin 
which share homology with human counterparts are 
exploited in the XAV construction [9–14].
At the R.E. Kavetsky Institute of Experimental Pathol-
ogy, Oncology and Radiobiology (IEPOR) of the National 
Academy of Science of Ukraine XAV based on chicken 
embryo proteins (CEP) is under deve lopment. 
It is known that anticancer vaccines based on one 
or several antigens can lead to an immune edi ting of the 
tumor so that it loses antigens targeted by the vac-
cine. Moreover, polyantigenic vaccines potentially can 
elicit an immune response to a wider range of cancer 
antigens including unidentified ones [15]. That is why 
the vaccine which is being constructed is designed 
to be polyantigenic and is based on proteins extracted 
from the chicken embryo. In preliminary experiments, 
it was shown that blood serum of mice bearing different 
tumor strains has antibodies which react with CEP [16]. 
When injected to intact mice CEP caused no side effect 
or allergy reactions [17]. The aim of the current work 
is to evaluate the anticancer activity of CEP-based vac-
cine administered by different vaccination schedules.
MATERIALS AND METHODS
The study has been carried out on male C57Bl/6 mice 
2–2.5 months old weighing 19–20 g, bred in the 
IEPOR. The use and care of the experimental animals 
have been performed in accordance with the standard 
international rules of biologic ethics and was approved 
by Institutional Animal Care and Use Committee [18, 
19]. The anticancer and antimetastatic efficacy of CEP 
was examined when vaccination was applied prior to tu-
mor cells injection (prophylactic schedule), after tumor 
transplantation (therapeutic vaccination) or after tumor 
removal (post surgery vaccination). Lewis lung carci-
noma (LLC) was used as the model of tumor growth.
CEP was prepared as follows [20]: 7 days chicken 
embryos were rinsed two times briefly in cold 0.9% 
NaCl solution, homogenized and then extracted with 
0.9% NaCl solution containing 0.1% EDTA, for 60 min 
at 4 °C by agitation. Following the extraction, chicken em-
bryo tissue was removed by centrifugation at 1.500 g for 
30 min. The resulting supernatant was collected and 
frozen at −20 °C. Tumor associated antigens of LLC 
(LLC-Ag) were prepared by three consecutive cycles 
of freezing and melting of cell suspension. Following 
the last melting, cell debris was removed by centrifuga-
tion at 1.500 g for 30 min. The resulting supernatants 
were collected and frozen at −20 °C. The concentration 
of proteins in the extracts was measured by Greenberg 
and Craddock assay [21]. The same extracts were used 
in all the experiments described in the article.
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Irrespective of vaccination schedule, CEP or LLC-
Ag immunizations were performed s.c. with 0.3 ml so-
lution per mouse (protein concentration 0.3 mg/ml).
According to the prophylactic experiment, mice 
were immunized with CEP or LLC-Ag (three weekly 
injections); LLC cells were transplanted 30 days after 
the last immunization.
Therapeutic vaccination has been performed 
by three different schemes: on the 1st, 8th, 15th days 
(group #1); on the 7th, 14th, 28th days after the tumor 
cell transplantation (group #2); in the third group, vac-
cination started when the tumor nodule had become 
clearly palpable and was followed with two additional 
injections on the 3rd and 10th days after the first vac-
cination (that corresponds to the 12th, 15th and 22nd 
days after the tumor transplantation).
Post surgery vaccination started on the 1st, 8th, 15th 
days after the tumor removal, which corresponds to the 
18th, 24th and 31st days after tumor transplantation.
In the prophylactic and treatment vaccination experi-
ments cancer cells suspension was injected i.m. into the 
right hind leg at a dose of 4 × 105 cells/mouse. Unvac-
cinated mice with the tumor were used as the control.
In the post surgery vaccination experiment, LLC cells 
were injected per foot at a dose of 2.5 × 105 cells/mouse. 
The tumor removal was performed on the 17th day after 
the tumor transplantation. Mice which have undergone 
surgical tumor removal but received no vaccination are 
referred as the control.
Tumor dimensions were measured with calipers, 
and tumor volumes were calculated according to the 
formula: 
Tumor volume = 2/3 π • width2 • length.
The Index of Tumor Growth Inhibition (ITGI) was 
calculated according to the formula:
ITGI = 100%•(Vcontrol mice — Vimmunized mice) / Vcontrol mice,
where Vcontrol mice and Vimmunized mice stand for the 
mean tumor volume in control and immunized mice 
respectively.
To assess metastasis burden mice were sacrificed 
and in each animal lungs were removed; surface lung 
metastases were counted and measured. The metas-
tases volume was calculated as following: 
V = 4πr3/3, 
where r — stands for the metastases radius. 
The percentage of mice bearing metastases is referred 
as metastases rate. The mean number of metastases 
was calculated per all the mice in group and per mice 
bearing metastases.
Metastasis Inhibition Index (MII) was calculated 
as following:
MII = 100% • (Аc • Вc – Аi • Вi) / (Аc • Вc),
where Аc and Аi stand for the number of mice be-
aring lung metastases in groups of control and immu-
nized mice respectively. Вc and Вi stand for the mean 
number of lung metastases in groups of control and 
immunized mice respectively [22]. The results were 
analyzed for statistical significance by paired t-test 
using StatSoft STATISTICA 7.0. Values p < 0.05 were 
considered as statistically significant [23, 24]. The 
data in figures and tables are presented as M ± SD.
RESULTS
The anticancer activity of CEP applied before 
tumor transplantation (prophylactic immuniza-
tion). CEP or LLC-Ag were injected three times with 
one-week intervals. Then 30 days after the last immu-
nization, LLC was transplanted into both unvaccinated 
animals (the control) and mice vaccinated with CEP 
or LLC-Ag. LLC tumor appeared in 81.0% (17 out of 21) 
of the control mice (Table 1). In the treatment groups, 
77.8% (7 out of 9) and 81.8% (9 out of 11) of mice im-
munized with LLC-Ag or CEP, respectively, developed 
LLC tumors. The difference between all the groups was 
not significant. The latent period of tumor development 
was shorter (p < 0.05) in the group of the control mice 
(7.8 days) compared to the mice pre-vaccinated with 
LLC-Ag (10.0 days) or CEP (10.9 days).
Table 1. The latent period of tumor development and tumor transplanta-
tion efficacy in the vaccinated and control LLC-bearing mice
Group Tumor transplantation efficacy, %
Latent period of tumor 
development, days
Control 81.0 ± 13.1 7.8 ± 0.4
LLC-Ag 77.8 ± 13.9 10.0 ± 0.7*
CEP 81.8 ± 11.6 10.9 ± 0.6*
Note: *р < 0.05 compared to the control group.
The tumor growth kinetics is shown in Fig. 1. Du-
ring the experiment, the smallest tumor volume was 
observed in the group of mice immunized with CEP 
(p < 0.05 compared to the control group). In the group 
of CEP-immunized mice, the ITGI reached 35.8–48.8% 
depending on time after the tumor transplantation. 
The tumor volume of mice immunized with LLC-Ag did 
not differ significantly compared to both control and CEP-
immunized mice. In the group of LLC-Ag-immunized mice, 
the maximal ITGI (28.4%) was observed on the 14th day 
after the tumor transplantation (Table 2).
On day 28 after LLC transplantation, all the mice 
of the control and treatment groups were euthanized 
so the metastases rate to be evaluated. The results 
are shown in Table 3.
In the mice vaccinated with CEP, 73.4% reduc-
tion of the mean metastasis volume was registered, 
in particular, 51.5 and 72.1% decrease of the metas-
tases number per mouse or per mouse in the group 
correspondingly. So, in this group MII reached 59.5% 
per metastases-bearing mouse and 71.1% per group. 
Contrary to CEP, LLC-Ag vaccination was not effective 
against metastases development.
Table 2. Tumor volume and ITGI in control and vaccinated before tumor transplantation mice bearing LLC
Group Parameter Days after LLC transplantation10 14 17 21 24 28
Control Tumor volume, mm3 165.0 ± 22.5 493.7 ± 62.2 981.0 ± 120.1 1523.7 ± 85.1 2087.8 ± 114.1 2492.4 ± 268.2
LLC-Ag Tumor volume, mm3 163.5 ± 35.8 353.6 ± 65.0 856.6 ± 125.0 1172.2 ± 190.3 1550.9 ± 291.2 1891.5 ± 332.7
ITGI, % 0.9 27.4 12.7 23.1 25.7 24.1
CEP Tumor volume, mm3 84.6 ± 8.3 301.5 ± 54.6 512.8 ± 73.0 892.3 ± 132.0 1321.1 ± 215.3 1600.8 ± 246.7
ITGI, % 48.8 38.9 47.7 41.4 36.7 35.8
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Fig. 1. The growth kinetics of LLC in control and pre-vaccinated 
animals
Table 3. Metastasis burden in control and vaccinated before tumor trans-
plantation mice bearing LLC
Group Metastases rate, %
Volume 
of metasta-
ses, mm3
Number of metastases
per mouse 
bearing me-
tastases
per group
Control 70.0 ± 14.5 38.9 ± 13.9 20.6 ± 6.5 14.4 ± 5.5
LLC-Ag 88.9 ± 9.9 30.4 ± 10.3 22.9 ± 7.1 22.9 ± 7.1
CEP 50.0 ± 20.4 10.4 ± 3.0 11.7 ± 3.5 5.8 ± 3.2
The anticancer activity of the CEP-based vac-
cination applied after the tumor transplantation 
(therapeutic vaccination). Therapeutic vaccination 
with CEP has been performed according to three dif-
ferent schedules of vaccination (described in details 
in the Materials and Methods section). Any of immuni-
zation schedules appeared to be superior in transplan-
tation efficacy and latent period of LLC development, 
as far as 85.9–89.6% of the vaccinated and control 
mice developed tumors on the 9–11th day after the LLC 
cells transplantation.
When it comes to the tumor volume, the most evi-
dent effect on tumor growth was observed in the group 
of mice vaccinated according to the schedule #1 (Fig. 2). 
Compared to the control group, the difference was sig-
nificant (p < 0.05) till the 20th day after the tumor chal-
lenge. The ITGI reached 53.13% on 14th day after the 
LLC transplantation and was decreasing slowly till the 
28th day of the experiment. Although the ITGI (42.1%) 
observed at this time point of the follow-up period 
(the 28th day after the LLC transplantation) was the 
lowest for the group #1, it remained to be the highest 
among the other groups. The tumor volume of the mice 
vaccinated according to the two other schedules did 
not differ significantly compared with the control group.
On day 28 after the tumor transplantation, all 
the mice were euthanized to assess the metastasis 
 loading (Table. 4). The results of the group #1 were 
 out-standing. In this group, the lowest mean metasta-
ses number per group was recorded (0.05 < p < 0.1 com-
pared to the control group). The mean metastases 
volume was by 54.4% lower than that in the control 
group. So, the MII in group #1 reached 77.6% (per 
group) or 66.3% (per mice bearing metastases) and 
was the highest among all the treatment and control 
groups. In other treatment groups, the results did not 
differ significantly from that of the control group.
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Fig. 2. The tumor growth kinetics in animals vaccinated with 
CEP and control mice
It is worth mentioning that only in the group #1 all 
the mice were still alive till the end of the experiment 
(28 days after tumor transplantation). The worst sur-
vival rate was in the group #3 (here the vaccination 
started after the tumor nodule could be palpable), 
in which 50% of immunized mice died before the ex-
periment termination.
Table 4. Indexes of metastasis rate in animals vaccinated by different 
therapeutic schedules and in control LLC-bearing mice
Group Metastases rate, %
Volume 
of metasta-
ses, mm3
Number of metastases
per mouse 
bearing me-
tastases
per group
Control 85.7 ± 12.4 10.1 ± 5.4 10.4 ± 3.4 10.4 ± 3.4
#1 66. 7 ± 19.2 4.6 ± 3.9 4.5 ± 2.0 3.0 ± 1.6*
#2 80.0 ± 19.4 31.3 ± 15.7 17.7 ± 8.4 13.2 ± 7.6
#3 66.7 ± 27.2 13.2 ± 6.2 23.0 ± 8.5 15.3 ± 10.3
Note: *0.05 < р < 0.1 compared to the control group.
The anticancer activity of CEP applied after 
the tumor resection (post surgical therapeutic 
vaccination). As far as the most prominent anticancer 
results were observed in the group of mice immunized 
on the 1st, 7th and 14th days after tumor transplantation 
(group #1), the same schedule was chosen to be ap-
plied in the study of post surgical therapeutic vaccina-
tion. Mice were transplantated with LLC cells (per foot); 
on the 17th day after transplantation the tumor nodule 
was removed. All the mice were divided into two groups. 
The mice in the CEP group underwent vaccinations with 
CEP on the 1st, 7th and 14th days after tumor resection. 
On the 35th and 50th days after the tumor transplanta-
tion (the 18th and 34th days after the tumor removal, 
respectively) the mice of both (control and treatment) 
groups were euthanized to assess the metastases 
burden (Table 5).
Table 5. Metastasis indexes in mice vaccinated with CEP after surgical removal of LLC
Group
The day 18 after tumor removal The day 34 after tumor removal
Metastases 
rate, %
Volume of me-
tastases, mm3
Number of metastases Metastases 
rate, %
Volume of me-
tastases, mm3
Number of metastases
per mouse be-
aring metastases per group
per mouse be-
aring metastases per group
Control 72.7 ± 13.4 69.3 ± 25.8 16.5 ± 3.6 12.0 ± 3.5 66.7 ± 13.6 133.1 ± 98.5 4.2 ± 2.02 2.4 ± 1.12
CEP 27.3 ± 13.41 1.2 ± 0.91 3.7 ± 1.11 1.0 ± 0.61 15.4 ± 10.01 0.8 ± 0.4 1.5 ± 0.7 0.2 ± 0.2
Note: 1р < 0.05 compared to the control; 2р < 0.05 compared to the 18th day after tumor removal.
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In this experimental setting, CEP showed evident 
and long-lasting antimetastatic effect. Independently 
on observation time, CEP immunization led to reduc-
tion of the metastases rate, metastases number and 
volume. For example, on the 18th day after the tumor 
removal, only 27.3% of the immunized mice had me-
tastases, while in the control group this index reached 
72.7% (the difference was statistically significant). 
The metastases volume in the group of vaccinated 
mice was by 98.3% lower (p < 0.05) when compared 
to the control mice. The mean number of metastases 
per metastases-bearing mouse or per group in total 
was statistically significantly lower in the group of CEP 
vaccinated mice. So, MII reached 91.7% per mouse 
and 96.9% per group.
On the day 34th after the tumor removal, mice in the 
control group showed disease progression. For example, 
the metastases volume increased by 1.92 times, com-
pared with the 18th day after the tumor removal. The mean 
number of metastases slightly decreased possibly due 
to the merging of small metastases. The metastasis rate 
did not change significantly (66.7 ± 13.6 and 72.7 ± 13.4% 
of control mice had metastases on the 34th and 18th days 
after the tumor removal respectively).
On the other hand, mice immunized with CEP 
showed stabilization of metastatic process. In particu-
lar, the metastases volume was 0.8 ± 0.4 mm3 (to com-
pare, it was 1.2 ± 0.9 mm3 on the 18th day after the 
tumor removal); the metastases number per mouse 
bearing it was 1.5 ± 0.7 (3.7 ± 1.1 on the day 18th 
of examination). In control mice, metastasis rate in the 
group of vaccinated mice did not differ significantly 
from the previous point of observation.
So, we can assume that on the 18th day after the 
tumor removal almost all the mice (of both control and 
treatment groups) which were prone to develop me-
tastases developed them, as long as the metastasis 
rate did not differ significantly on the 18th and 34th days 
of observation. But the metastasis rate was statistically 
lower in the CEP vaccinated group during all the experi-
ment (i.e. on the 18th and 34th days after tumor removal) 
compared to the control. What is important, the vac-
cinated mice showed inhibition of metastases growth, 
whereas in the control group the mean metastases vo-
lume increased by almost 2 times. As a result, the mean 
metastases volume in the group of immunized mice was 
by 94.4% lower than that in the control group. In the 
CEP group, the MII calculated per group was equivalent 
to 97.8%. So, the antimetastatic effect of CEP-based 
vaccination was observed for a prolonged period of time 
even after the termination of the vaccination.
DISCUSSION
So, as it was shown in the model of LLC, vaccination 
with CEP appears to have anticancer and antimeta-
static effects. In the previous experiments it has been 
shown that there were CEP-specific antibodies in the 
blood serum of mice bearing different tumor strains 
(LLC, sarcoma 37, Ehrlich carcinoma, melanoma 
B-16) [16]. The presence of CEP-specific antibodies 
in the blood serum of unimmunized tumor-bearing 
mice may be explained by at least two reasons: poly-
specific antibody circulation [25, 26] and the pre sence 
of some homologous proteins in CEP. It is known 
that some proteins of chicken origin share homology 
with mammals proteins, including that of human and 
mice [9, 10, 12, 27–29]. The anticancer effect of CEP 
seems to be based on the last assumption. Especially, 
it looks possible when we consider the antitumor and 
antimetastatic effects of CEP applied before the tu-
mor challenge — in so called prophylactic settings. 
According to the prophylactic schedule which was 
applied in the experiment, the tumor cell injection was 
performed on the 30th day after the last immunization. 
Till the 30th day after the CEP injection, the immune 
response induced by the immunization was expected 
to terminate [30], but immune memory cells had been 
already established [31]. The immune memory is ca-
pable of mounting a rapid response to subsequent 
antigen stimulation [32]. In the experiment, LLC cell 
suspension in the dose sufficient to induce tumors 
was used instead of the antigen re-challenge. Since 
a statistically significant prolongation of the latent pe-
riod of tumor development in the groups of immunized 
mice was observed, it points to the generation of the 
rapid immune response to the cancer cells injection. 
That is, the mice immunized with CEP or LLC-Ag in the 
prophylactic mode mounted a rapid immune response 
to cancer cells as if it was an antigen re-challenge.
Subsequently, the observed results indicate with 
high probability that CEP contains some proteins which 
share homology with LLC antigens and immunization 
with CEP leads to immune memory formation. More-
over, in terms of its antimetastatic activity, vaccination 
with CEP was much more effective than application 
of LLC-Ag. This finding can be considered as an ad-
ditional demonstration that xenogeneic homologous 
proteins are useful for breaking immune tolerance 
towards autologous cancer antigens.
In case of therapeutic immunization, the anticancer 
effect of CEP was evident only when applied at the very 
early stage of tumor formation (24 h after tumor cells in-
jection, group #1), when tumor burden is minimal. When 
vaccination was postponed to only 7 days (group #2) 
the anticancer effect could hardly be observed. Fur-
thermore, vaccination with CEP has no anticancer ef-
fect when applied to mice with the already established 
tumor (group #3). So, it can be concluded that without 
prior tumor removal the application of anticancer vac-
cine based on CEP will have a minimal anticancer ef-
fect in clinical settings. On the other hand, it confirms 
a generally acknowledged statement that benefit 
of an anticancer vaccine is most evident when it is ap-
plied in earlier and less aggressive disease settings, 
that is in settings of minimal residual disease [33, 34].
Owning to this, the third experiment — application 
of CEP after the surgical resection of the tumor — 
was conducted. In this case, CEP application had 
a pronounced and long-lasting antimetastatic effect. 
The number of metastases bearing mice and the mean 
Experimental Oncology 37, 197–202, 2015 (September) 201
metastases volume were significantly reduced in the 
group of treated mice. These effects were evident till 
the 34th day after the tumor removal — the day of the 
experiment termination. It should be mentioned that 
the mean metastases volume in the CEP group was 
60 and 168.5 times smaller than that of the control 
group on the 18th and 34th days after the tumor re-
section respectively. MII was very high and reached 
96.9 and 97.8% per group in total on the 18th and 34th 
day respectively. It can be assumed that this vaccine 
when applied after the surgical removal of a tumor may 
dramatically improve therapeutic efficacy of cancer 
treatment, as long as metastatic spread of a tumor 
is the main death cause of cancer patients [35].
It has been shown that some genes or proteins 
of chicken origin, when used as a xenogeneic vaccine, 
can elicit anticancer effect or tumor specific immune 
response. For example, xenogeneic vaccines based 
on chicken HSP70 [11], MMP-2 [10, 14], Tie-2 [9] 
or FGFR [12, 13] were effective in case of LLC [10, 14], 
fibrosarcoma Meth A [13, 10], hepatoma H22 [9, 10], 
melanoma B-16 [9], CT26 colon adenocarcinoma [14], 
canine cancer [11]. Anticancer effects of CEP are com-
parable with these of the vaccines mentioned above. 
Whether CEP contains some of abovementioned pro-
teins or its anticancer effect is based on other antigens 
it remains to be elucidated.
CONCLUSION
Vaccination based on CEP exhibited both prophy-
lactic and therapeutic anticancer effects. The last one 
is more pronounced when the vaccination starts shortly 
after the primary tumor resection. In this case, the MII 
reaches 91.7%. So, CEP are suitable to be used in xe-
nogeneic cancer vaccine construction.
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